富祥药业拟出让上海凌富39.2%股权 回笼资金

Core Viewpoint - The company plans to transfer its 39.20% stake in Shanghai Lingfu Pharmaceutical Research Co., Ltd. to Shanghai Lingkai Technology Co., Ltd. for a price of 42.77 million yuan, aiming to enhance liquidity and reduce investment risks [1] Group 1 - The transaction will result in the company no longer holding any equity in Shanghai Lingfu [1] - The purpose of the share transfer is to achieve capital recovery and concentrate resources to strengthen the core competitiveness of the main business [1] - The company expects to optimize its investment structure to further enhance asset liquidity and overall risk resistance [1]